• Je něco špatně v tomto záznamu ?

Expression of c-MET protein in various subtypes of hepatocellular adenoma compared to hepatocellular carcinoma and non-neoplastic liver in human tissue

G. Szparecki, T. Ilczuk, N. Gabzdyl, E. Stocka-Łabno, B. Górnicka

. 2017 ; 63 (4) : 146-154.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18030383

Hepatocellular adenoma (HA) is a benign neoplasm of the liver, whose aetiopathogenesis is little known. Newest research allowed dividing all cases into three types based on molecular characteristics: inflammatory HA, HA with HNF1A mutation, β-catenin-mutated HA. The clinical significance of HA is chiefly due to the possibility of malignant transformation into hepatocellular carcinoma (HCC). The aim of the present study was to immunohistochemically assess the expression pattern and level of c-MET protein in hepatocellular adenoma (taking into account its status of Wnt/β-catenin pathway functioning) and intertwining the results into a wider pattern of expression in non-neoplastic liver and hepatocellular carcinoma of various histological grades. It was found that expression of c-MET in poorly-differentiated HCC was significantly higher than in non-neoplastic liver and well- to moderately-differentiated HCC. The expression in HA was variable and differed between molecular subtypes of this neoplasm: inflammatory and HNF1A mutation-associated type are characterized by overexpression of c-MET to an extent comparable with poorly-differentiated HCC, whereas Wnt/β-catenin dysfunction-associated type lacks overexpression, and the amount of c-MET protein accumulated in its cells is similar to the levels in non-neoplastic tissue and well- to moderately-differentiated HCC. These findings suggest that c-MET overexpression in HA is not an early event in hepatocarcinogenesis, but constitutes a divergent molecular pathway leading to neoplastic change compared to overexpression observed in the late stages of tumour progression.

000      
00000naa a2200000 a 4500
001      
bmc18030383
003      
CZ-PrNML
005      
20180920150254.0
007      
ta
008      
180904s2017 xr ad f 000 0|eng||
009      
AR
035    __
$a (PubMed)29256857
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Szparecki, G. $u Department of Pathology, Medical University of Warsaw, Poland.
245    10
$a Expression of c-MET protein in various subtypes of hepatocellular adenoma compared to hepatocellular carcinoma and non-neoplastic liver in human tissue / $c G. Szparecki, T. Ilczuk, N. Gabzdyl, E. Stocka-Łabno, B. Górnicka
520    9_
$a Hepatocellular adenoma (HA) is a benign neoplasm of the liver, whose aetiopathogenesis is little known. Newest research allowed dividing all cases into three types based on molecular characteristics: inflammatory HA, HA with HNF1A mutation, β-catenin-mutated HA. The clinical significance of HA is chiefly due to the possibility of malignant transformation into hepatocellular carcinoma (HCC). The aim of the present study was to immunohistochemically assess the expression pattern and level of c-MET protein in hepatocellular adenoma (taking into account its status of Wnt/β-catenin pathway functioning) and intertwining the results into a wider pattern of expression in non-neoplastic liver and hepatocellular carcinoma of various histological grades. It was found that expression of c-MET in poorly-differentiated HCC was significantly higher than in non-neoplastic liver and well- to moderately-differentiated HCC. The expression in HA was variable and differed between molecular subtypes of this neoplasm: inflammatory and HNF1A mutation-associated type are characterized by overexpression of c-MET to an extent comparable with poorly-differentiated HCC, whereas Wnt/β-catenin dysfunction-associated type lacks overexpression, and the amount of c-MET protein accumulated in its cells is similar to the levels in non-neoplastic tissue and well- to moderately-differentiated HCC. These findings suggest that c-MET overexpression in HA is not an early event in hepatocarcinogenesis, but constitutes a divergent molecular pathway leading to neoplastic change compared to overexpression observed in the late stages of tumour progression.
650    _2
$a dospělí $7 D000328
650    _2
$a hepatocelulární karcinom $x metabolismus $7 D006528
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hepatocytární jaderný faktor 1-alfa $x genetika $7 D051538
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a játra $x metabolismus $x patologie $7 D008099
650    _2
$a nádory jater $x metabolismus $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a protoonkogenní proteiny c-met $x metabolismus $7 D019859
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ilczuk, T. $u Department of Pathology, Medical University of Warsaw, Poland.
700    1_
$a Gabzdyl, N. $u Department of Pathology, Medical University of Warsaw, Poland.
700    1_
$a Stocka-Łabno, E. $u Department of Pathology, Medical University of Warsaw, Poland.
700    1_
$a Górnicka, B. $u Department of Pathology, Medical University of Warsaw, Poland.
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 63, č. 4 (2017), s. 146-154
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29256857 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5850/fb2017a0021.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y 4 $z 0
990    __
$a 20180904 $b ABA008
991    __
$a 20180918144603 $b ABA008
999    __
$a ok $b bmc $g 1335303 $s 1027354
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 63 $c 4 $d 146-154 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20180904

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...